Evidence map›Paper›PMID 42614572›Full record

ArticleNAM journal2026

ASPIS Academy: A blueprint for building early-career researcher networks to advance NAM-based risk assessment.

Luiz Ladeira, Ruben Martinez, Gaëlle Hayot, Barira Islam, Christina H J Veltman, Julen Sanz-Serrano, Hiba Khalidi, Rita Ortega-Vallbona, Marie Corradi, Eike Cöllen and 17 more

Abstract read
In one paragraph

Article in NAM journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Luiz LadeiraBiomechanics Research Unit, GIGA Institute, University of Liège, Belgium.
Ruben MartinezLeitat technological center, Spain.
Gaëlle HayotKarlsruhe Institute of Technology, Germany.
Barira IslamCertara Predictive Technologies, UK.
Christina H J VeltmanCentre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
Julen Sanz-SerranoVrije Universiteit Brussel, Belgium.
Hiba KhalidiCertara Predictive Technologies, UK.
Rita Ortega-VallbonaProtoQSAR SL, Spain.
Marie CorradiHU - University of Applied Sciences Utrecht, the Netherlands.
Eike CöllenUniversity of Konstanz, Germany.
A Melina SteinbachGerman Federal Institute for Risk Assessment (BfR), Germany.
Klára GabrišováInstitute of Experimental Pharmacology & Toxicology, Centre of Experimental Medicine, Slovak Academy of Sciences, Slovakia.
Peter PôbišInstitute of Experimental Pharmacology & Toxicology, Centre of Experimental Medicine, Slovak Academy of Sciences, Slovakia.
Devon BarnesUtrecht University, the Netherlands.
Shaleen GlasgowCentre for Environmental Research and Justice, and School of Biosciences, University of Birmingham, UK.
Marije NiemeijerDivision of Cell Systems and Drug Safety, Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlands.
Julia Dominika ZajacVrije Universiteit Brussel, Belgium.
Agata Ormanin-LewandowskaCentre for Environmental Research and Justice, and School of Biosciences, University of Birmingham, UK.
Martijn J MonéDivision of Cell Systems and Drug Safety, Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlands.
Bob van de WaterDivision of Cell Systems and Drug Safety, Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlands.
John K ColbourneCentre for Environmental Research and Justice, and School of Biosciences, University of Birmingham, UK.
Mathieu VinkenVrije Universiteit Brussel, Belgium.
Silvia TangianuCenter for Alternatives to Animal Testing in Europe, Konstanz, Germany.
Helena KandarovaInstitute of Experimental Pharmacology & Toxicology, Centre of Experimental Medicine, Slovak Academy of Sciences, Slovakia.
Giorgia PalloccaHumane World for Animals Europe, Belgium.
François BusquetALTERTOX, Belgium.
Eliska KuchovskaIUF - Leibniz Research Institute for Environmental Medicine, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemical risk assessment is moving away from traditional animal-based testing toward New Approach Methodologies (NAMs) that are more human-relevant, efficient, and aligned with the replacement, reduction, and refinement of animal use. This transition depends not only on new methods and technologies, but also on the researchers who will develop, apply, and promote them. Early-career researchers (ECRs) are central to this effort, yet they often work within fragmented professional networks and have limited opportunities for mentoring, visibility, and leadership. The ASPIS Academy (AA) was established within the ASPIS cluster, comprising the EU Horizon 2020-funded projects ONTOX, RISK-HUNT3R, and PrecisionTox, to support ECRs working on NAM-based chemical risk assessment. Built and coordinated by ECRs with support from senior advisors, AA evolved from an initial idea into an operational network offering training, mentoring, mirroring, twinning, communication, dissemination, and collaboration activities. Its development was shaped not only by strategic planning, but also by the practical realities of voluntary coordination and the changing needs of ECRs across large multidisciplinary consortia. This manuscript presents the establishment, growth, and legacy planning of AA as a case study for building ECR networks in collaborative research environments. We describe the decisions, challenges, lessons learned, and activities that helped the network become useful to its community and provide a practical blueprint for other consortia seeking to support the next generation of NAM scientists. The AA experience demonstrates that empowering ECRs to lead can strengthen scientific communities and accelerate the uptake of NAMs.

Indexed as

Chemical risk assessmentEarly-career researchersNew approach methodologiesScientific networkingTraining and mentoring

Identifiers

PMID42614572
PMCPMC13482515

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.